Applied DNA Sciences, Inc. Partners with HDT Bio to Enhance Rapid Vaccine Production

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, has been awarded a contract by HDT Bio to advance rapid vaccine development. This collaboration, under the ‘Project NextGen: Enabler’ initiative, aims to significantly shorten vaccine production times to meet critical needs during health crises.

The contract involves Applied DNA supplying Linea™ DNA IVT templates for use with HDT Bio’s LION™ repRNA vaccination platform. The primary goal is to prove that it is feasible to manufacture 1,000 doses of a functional vaccine within just seven days, a crucial capability during outbreaks or pandemics. This effort represents a pivotal step towards decentralized and accelerated vaccine manufacturing.